ASSIGNMENT AND EXCHANGE AGREEMENTAssignment and Exchange Agreement • November 29th, 2023 • Adhera Therapeutics, Inc. • Pharmaceutical preparations • New York
This ASSIGNMENT AND EXCHANGE AGREEMENT (this “Agreement”), dated as of November 22, 2023, is entered into by and among Biodexa Pharmaceuticals, PLC, a public limited company organized under the laws of England and Wales (“Buyer”), and Adhera Therapeutics, Inc., a Delaware corporation (the “Company”), and the holders of secured notes issued by the Company set forth on Schedule 1 hereto (the “Secured Noteholders”). The Company, Buyer and the Secured Noteholders are sometimes referred to herein collectively as the “Parties” and each individually as a “Party.” Capitalized terms used herein but not otherwise defined shall have the meaning set forth in Article I.
Biodexa Pharmaceuticals PLCAdhera Therapeutics, Inc. • November 29th, 2023 • Pharmaceutical preparations
Reference is made to that certain Assignment and Exchange Agreement, dated as of the date hereof, by and among Biodexa Pharmaceuticals PLC, a public limited company organized under the laws of England and Wales (“Buyer”), Adhera Therapeutics, Inc., a Delaware corporation (the “Company”), and the holders of secured notes issued by the Company set forth on Schedule 1 thereto (the “Agreement”). Capitalized terms used, but not otherwise defined, herein shall have the meaning given to such terms in the Agreement.
